Immunome Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Immunome Inc 's ROA in the second quarter of 2026?
Immunome Inc recorded a cumulative net loss of $-254 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -46.9%.

However, within the Healthcare sector 543 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3899, from total ROA ranking in the first quarter of 2026 at 4614.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	90.82 %	85.52 %	194.42 %	19.17 %	2.04 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-254	-225	-212	-223	-212
Return On Assets (TTM)	-46.9 %	-47.28 %	-52.63 %	-76.66 %	-76.26 %
IMNM's Total Ranking	# 3899	# 4614	# 4247	# 4300	# 4367
Total Assets (TTM) in million	565	620	684	299	296
Seq. Total Assets Change	-8.78 %	-9.45 %	128.64 %	1.04 %	-11.31 %
Seq. Net Income Change	-	-	-	-	-

IMNM's 5 Years Annual ROA >> Back to IMNM Management Effectiveness >> Compare IMNM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 230
Sector	# 544
Overall	# 3857

Return On Assets Statistics
High	Average	Low
-22.39 %	-77.33 %	-153.94 %
(Jun 30 2021)		(Mar 31 2024)

Financial Statements
Immunome Inc 's Assets	$ 565 million	IMNM's Balance sheet
Immunome Inc 's Income	$ -73 million	Quarterly IMNM's Income Statement
IMNM's Income by Division		See IMNM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	193.86 %	21.78 %	693.9 %	-60.05 %	35.18 %
Total Assets in million	683	232	191	24	60
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-212	-293	-107	-38	-25
Annual Return On Assets	-31.09 %	-126.01 %	-55.95 %	-156.03 %	-41.06 %

IMNM's 5 Years Annual ROA >> Back to IMNM Management Effectiveness >> Compare IMNM ROA to its Competitors

More Return On Assets Ratios
IMNM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IMNM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IMNM's Competitors
Subscribers only: Roa for Immunome Inc 's Suppliers
Subscribers only: Return On Assets for IMNM's Customers

You may also want to know
IMNM's Roi	IMNM's Inventory Turnover Ratio	IMNM's Growth Rates	IMNM's Dividend Comparisons
	IMNM's Profitability Ratios	IMNM's Asset Turnover Ratio	IMNM's Dividend Growth
IMNM's Roe	IMNM's Valuation Ratios	IMNM's Financial Strength Ratios	IMNM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T00:07:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.